Letter from FDA outlining deficiencies for lead drug causes Axsome stock to crater. Is a CRL on the way?

The FDA has concerns with Axsome’s lead and potential blockbuster drug to treat major depressive disorder, which sent the company’s stock price down by more than 40% early Monday.